Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Overview

Información sobre este estudio

The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Only female patients are eligible
  2. Patients must be 18 years of age or older
  3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification
  4. Patients must have been on stable birth control if premenopausal.
  5. Patients are able and willing to provide written informed consent after the nature of the study is fully explained

Exclusion Criteria:

  1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
  2. Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure
  3. Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment
  4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
  5. Patients previously having undergone hair transplant surgery prior to study entry
  6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women
  7. Patients who have taken spironolactone in the 3 months prior to study participation
  8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed
  9. Patients with ongoing infectious disease, including HIV and hepatitis
  10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes
  11. Patients participating in a study of an experimental drug or medical device within 30 days of study entry
  12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.
  13. Patients taking antiaggregating therapy
  14. Patients on anticoagulant therapy
  15. Patients with tendency to keloid formation
  16. Patients with uncompensated diabetes
  17. Patients with active skin disease or skin infection at intended treatment areas

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Alison Bruce, M.B., Ch.B.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20424745

Mayo Clinic Footer